A Cost-Effectiveness Analysis of Abemaciclib in Combination with Adjuvant Endocrine Therapy for HR+, HER2–, Node-Positive, High-Risk Early Breast Cancer
Despite the ICER exceeding usual willingness-to-pay (WTP) levels in the UK, a consequence of using list prices, the CE model utilizing the latest data cut from the monarchE trial, demonstrated that the upfront cost of abemaciclib reduces the risk of a terminal breast cancer prognosis and its associated cost and quality of life impact. The addition of 2 years of abemaciclib provides an option for the treatment of HR+, HER2-, node-positive, high-risk EBC.
Authors
- Waleed Badreldin
- S. Tempelaar
- Ann E. McCullough (ORCID: https://orcid.org/0000-0003-3778-4534)
- Peter S Hall (ORCID: https://orcid.org/0000-0001-6015-7841)
- Alison Davie (ORCID: https://orcid.org/0000-0003-2256-8919)
- Esra Şükran Çakar (ORCID: https://orcid.org/0000-0002-3240-0557)
- S Traoré (ORCID: https://orcid.org/0000-0002-1479-2737)
- Elisabeth Fenwick
- Astrid Torstensson
Institutions
- Eli Lilly (United States) (US)
- The Open Group (GB)
- Eli Lilly (United Kingdom) (GB)
- Institute of Genetics and Cancer (GB)
- Open University of the Netherlands (NL)
Publication Details
- Journal
- Advances in Therapy
- Published
- 2025-04-08
- DOI
- https://doi.org/10.1007/s12325-025-03164-0
- Citations
- 4
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 6.07
Funders
- Eli Lilly and Company